Entering text into the input field will update the search result below

OncoSec +6% on introducing new technology for deep visceral lesions with IL-12

  • OncoSec Medical (NASDAQ:ONCS) has developed a new, propriety technology to potentially treat pancreatic, liver and other difficult to treat visceral lesions through the direct delivery of plasmid-based interleukin-12 (IL-12) with a new Visceral Lesions Applicator (VLA).
  • The company's new technology was published in a white paper titled "Parachuting Behind Enemy Lines: OncoSec's Attack on Visceral Tumors via Its New Visceral Lesion Applicator."
  • The Company plans to introduce the new VLA, deploying its new product candidate, SPARK, and improved generator, APOLLO, in early 2020.
  • Shares are up 6% premarket.

Recommended For You

About ONCSQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ONCSQ--
OncoSec Medical Incorporated